OGM can identify novel translocations leading to gene disruption or new fusions involving genes that can be important drivers of cancer pathogenesis and also of targeted therapy [3]; one such example is a novel balanced translocation involving UBE3C and MSI2 fusion identified as a single chromosomal rearrangement in acute myeloid leukemia (AML) [3]. This evidence concerns the gene MSI2 and acute myeloid leukemia.